Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China

Table 2 Model inputs of cohort characteristics, transition probability, costs, and utility

Parameters	Value	Ref.
Cohort characteristics
Age	30	Xu et al[5], 2023
Female (%)	46.65	Xu et al[5], 2023
Weight (kg)	60
Transition probability
Post-surgical remission	52.68%	Bouhnik et al[13], 2023
Post-surgical active disease	47.32%	Bouhnik et al[13], 2023
Recurrence after surgery	3.50%	Bouhnik et al[13], 2023
Death rate	Age-gender-specific death rate	Cai[20], 2012
Costs
Infliximab	$204.40/100 mg IV	Induction: 5 mg/kg, 0/2/6 weeks; maintenance: 5 mg/kg, every 8 weeks
Adalimumab	$144.71/40 mg SC	Induction: 160 mg 0 week, 80 mg 2 weeks; maintenance: 40 mg, every 2 weeks
Ustekinumab	$302.11/130 mg IV $958.59/90 mL SC	Induction: 390 mg; maintenance: 90 mg, every 12 weeks
Vedolizumab	$699.27/300 mg IV	Induction: 300 mg, 0/2/6 weeks; maintenance: 300 mg, every 8 weeks
SAE	$1507.46/cycle	Zhou et al[11], 2021
Surgery	$9849.27/cycle	Average colectomy cost of China Healthcare Security Diagnosis Related Group 2.0
Conventional therapy (induction)	$125.42/cycle	Inflammatory Bowel Disease Group[2], 2024
Conventional therapy (maintenance)	$103.79/cycle	Inflammatory Bowel Disease Group[2], 2024
Utility
Active disease	0.40	Bouhnik et al[13], 2023; Lindsay et al[18], 2008
Clinical remission	0.83	Bouhnik et al[13], 2023; Lindsay et al[18], 2008
Clinical response	0.55	Bouhnik et al[13], 2023; Lindsay et al[18], 2008
Surgery	0.40	Bouhnik et al[13], 2023
Post-surgical remission	0.67	Bouhnik et al[13], 2023; Lindsay et al[18], 2008
Post-surgical active disease	0.40	Bouhnik et al[13], 2023
Disutility of SAE	0.07	Worbes-Cerezo et al[19], 2019

IV: Intravenous injection; SAE: Serious adverse event; SC: Subcutaneous injection.